FDA approves COVID-19 antigen test, first chikungunya vaccine
The Food and Drug Administration Nov. 9 cleared for marketing the Flowflex COVID-19 Antigen Home Test, the first COVID-19 antigen test and second COVID-19 at-home test to successfully complete traditional premarket review.
In other news, the agency yesterday approved the first chikungunya vaccine for adults at increased risk of exposure to the virus, primarily through travel to regions of Africa, Southeast Asia and the Americas where mosquitos carry the virus. The Centers for Disease Control and Prevention last year reported 81 travel-associated cases. Locally acquired cases were reported in Florida in 2014 and Texas in 2015.
Related News Articles
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
Flu cases are growing or likely growing in 39 states, according to the latest Centers for Disease Control and Prevention data from Nov. 11. COVID-19…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…